“Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s47. Accessed April 19, 2026. https://skin.dermsquared.com/skin/article/view/1802.